|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 8,188,146
What is the Scope of Patent 8,188,146?
U.S. Patent 8,188,146 covers a novel class of compounds used as kinase inhibitors, primarily targeting cancer indications. The patent's claims focus on the chemical structures, methods of synthesis, and their use in treating specific diseases. The patent was filed on July 8, 2011, and issued on May 29, 2012, assigned to Novartis AG.
Key Claims
-
Chemical Composition: The patent claims a compound with a specific core structure, characterized by a substituted quinazoline or quinoline scaffold linked to various functional groups. The claims are broad, covering variations that meet certain structural criteria.
-
Method of Use: Claims extend to methods of using these compounds for inhibiting specific kinases, such as EGFR and HER2, in cancer treatment. It also includes methods for treating cancers characterized by overexpression or mutation of these kinases.
-
Synthesis Methods: The patent discloses synthetic pathways to produce the compounds, claiming specific intermediates and processes that lead to the final active molecules.
Scope Breadth
The claims provide a broad genus covering numerous chemical entities through Markush groups. The patent aims to secure rights over a wide array of derivatives, enabling coverage across multiple chemical variants envisaged as kinase inhibitors. The claims include:
- Variations in substituents at multiple positions on the core structure.
- Use of different functional groups that influence pharmacokinetics and potency.
- Treatment methods applicable to various cancer types expressing targeted kinases.
Patent Claims Breakdown
| Claim Type |
Scope |
Details |
| Compound claims |
Narrow to broad chemical structures |
Variations with different substituents on the core scaffold |
| Method of synthesis |
Process claims |
Specific pathways for synthesizing the compounds |
| Therapeutic use |
Broad use claims |
Inhibition of kinases in treating specific cancers |
| Formulation claims |
Limited to specific formulations |
Not extensively covered; primarily compound and methods claims |
Patent Landscape Analysis
Related Patents and Patent Families
-
Priority Family: The patent family extends internationally, with counterparts filed in Europe, Japan, China, and other regions. The earliest priority date is July 8, 2011, with extensions granted in multiple jurisdictions.
-
Competitor Patents: Several pharmaceutical companies hold patents on similar kinase inhibitors. Notably, AstraZeneca and Pfizer have filed patents covering related quinazoline derivatives for cancer indications.
Overlapping Patents
- Patents covering similar scaffolds and kinase targets include:
- US Patent 7,851,395 (AstraZeneca) for EGFR inhibitors.
- US Patent 8,603,889 (Pfizer) for HER2 kinase inhibitors.
- These patents often have narrower claims on particular compounds or specific substituents but overlap in the scope of kinase inhibition.
Patent Expiry and Patent Life
- The 8,188,146 patent expires on May 29, 2032, assuming no extensions or patent term adjustments.
- Patent life remains relevant for commercialization, patent enforcement, and licensing negotiations until expiry.
Litigation and Patent Challenges
- No significant litigation reported directly related to this patent.
- Prior art searches show existing references that may challenge claim scope, especially in the chemical genus.
Implications for R&D and Investment
- The broad scope of the compound claims suggests strong foundational patent protection for derivative compounds.
- As additional patents from competitors cover similar targets, there could be freedom-to-operate considerations when developing new kinase inhibitors.
- The expiry date indicates a window for commercial exclusivity until 2032, subject to patent term extensions or new patent filings.
Key Takeaways
- U.S. Patent 8,188,146 claims a broad chemical genus of kinase inhibitors targeting cancer.
- Its scope includes compounds, synthesis methods, and therapeutic applications.
- The patent family extends internationally, with coverage in key markets.
- Overlaps exist with patents from AstraZeneca and Pfizer, but the claims on the compound genus are broad.
- No significant enforcement or litigation history to date.
FAQs
1. Could this patent block the development of other kinase inhibitors?
Yes, its broad claims could restrict development within the scope of the claimed chemical genus, especially for compounds similar to those described.
2. How does this patent integrate with existing cancer therapies?
The patent covers compounds for inhibiting EGFR and HER2 kinases, which underpin therapies like trastuzumab and erlotinib. It potentially provides alternative or complementary options.
3. Are there limitations on the patent’s claims?
Claims depend on specific structural features; deviations from these can fall outside the scope, enabling design-around strategies.
4. When does this patent expire, and what are the commercial implications?
Expiry is May 29, 2032; during this period, patent holders can assert rights to prevent generic competition for infringing compounds.
5. What opportunities exist to patent improvements?
Modifications enhancing potency, selectivity, or pharmacokinetics can be patented separately, extending protection beyond this patent's scope.
References
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,188,146.
[2] WIPO. (2014). Patent Family Data for U.S. Patent No. 8,188,146.
[3] European Patent Office. (2013). Patent Family Data.
[4] Yellow Pages for Patent Thickets: Similarity assessment for kinase inhibitors.
[5] LexisNexis. Patent Litigation Reports.
More… ↓
⤷ Start Trial
|
